Hypercoagulabilty, venous thromboembolism, and death in patients with cancer: A multi-state model

Thrombosis and Haemostasis

Volumn 115, Issue 4, 2016, Pages 817-826

  Posch, Florian ^a   Riedl, Julia ^a   Reitter, Eva Maria ^a   Kaider, Alexandra ^a   Zielinski, Christoph ^a   Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Epidemiological studies; Venous thrombosis

Indexed keywords

D DIMER;

ADULT; AGED; ARTICLE; BRAIN TUMOR; BREAST TUMOR; CANCER STAGING; CANCER SURVIVAL; DEATH; FEMALE; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LUNG TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MODEL; NEOPLASM; OCCUPATION; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AUSTRIA; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; NEOPLASMS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; SURVIVAL ANALYSIS; THROMBOPHILIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84964770424     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-09-0758     Document Type: Article

References (18)

1. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122: 2011–2018.
2. Carrier M, Cameron C, Delluc A, et al. Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Thromb Res 2014; 134: 1214–1219.
3. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–634.
4. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601–609.
5. Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost 2012; 10: 1449–1451.
6. Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res 2012; 129 (Suppl 1): S85–87.
7. Ay C, Posch F, Kaider A, et al. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost 2014; Epub ahead of print.
8. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–2430.
9. Lotsch F, Konigsbrugge O, Posch F, et al. Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. Thromb Res 2014; 134: 1008–1013.
10. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381–387.
11. de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 2010; 99: 261–274.
12. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377–5382.
13. Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158–1164.
14. Diao D, Wang Z, Cheng Y, et al. D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One 2014; 9: e101125.
15. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients – risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042–1048.
16. Carrier M DI. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT): 2014. Available at: http://www.clinicaltrials.gov.
17. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of multi-state models and competing risks analysis. Hepatology 2014; Epub ahead of print.
18. Fiocco M, Putter H, van Houwelingen HC. Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models. Stat Med 2008; 27: 4340–4358.